<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05626127</url>
  </required_header>
  <id_info>
    <org_study_id>SYSKY-2022-267-01</org_study_id>
    <nct_id>NCT05626127</nct_id>
  </id_info>
  <brief_title>MRI-based Clinico-radiomics Predicting Lymph Node Metastasis Status of Hilar Cholangiocarcinoma</brief_title>
  <official_title>Evaluation of a MRI-based Clinico-radiomics Model in Predicting Lymph Node Metastasis Status of Hilar Cholangiocarcinoma Patients: a Prospective Diagnostic Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, observational diagnostic study aiming to assess multiparametric&#xD;
      MRI-based clinico-radiomics for identifying lymph node metastasis status in hilar&#xD;
      cholangiocarcinoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A preoperative tool capable of predicting lymph node metastasis status in hilar&#xD;
      cholangiocarcinoma is lacking and urgently needed for clinical practice. This study proposes&#xD;
      to establish and evaluate a machine-learning algorithms of multiparametric MRI-based&#xD;
      clinico-radiomics for identifying lymph node metastasis status in hilar cholangiocarcinoma.&#xD;
      This study will investigate the relationship between radiomic depth information and tumor&#xD;
      biological characteristics. The study includes the construction of capable MRI-based&#xD;
      clinico-radiomics prediction model and the validation of the prediction model.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 20, 2022</start_date>
  <completion_date type="Anticipated">December 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Lymph node metastasis status</measure>
    <time_frame>Baseline</time_frame>
    <description>The value of multiparametric MRI-based clinico-radiomics in predicting lymph node metastasis.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Hilar Cholangiocarcinoma</condition>
  <arm_group>
    <arm_group_label>Sun Yat-Sen Memorial Hospital of Sun Yat-sen University</arm_group_label>
    <description>The cohort of Sun Yat-Sen Memorial Hospital of Sun Yat-sen University is the validation cohort.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No interventions</intervention_name>
    <description>As this is a observational study, there are no interventions.</description>
    <arm_group_label>Sun Yat-Sen Memorial Hospital of Sun Yat-sen University</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who had resectable hilar cholangiocarcinoma and completed the upper abdomen MRI&#xD;
        examination before surgery.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The patient must sign an informed consent form;&#xD;
&#xD;
          2. Age 18-75 years old, both male and female;&#xD;
&#xD;
          3. ECOG performance status score (PS score) 0-2;&#xD;
&#xD;
          4. Hilar cholangiocarcinoma with resectable tumor lesions;&#xD;
&#xD;
          5. Complete the upper abdomen MRI examination before treatment;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Accompanied with other primary malignant tumors;&#xD;
&#xD;
          2. Patients who have neoadjuvant chemotherapy or other tumor-targeted therapies;&#xD;
&#xD;
          3. Incomplete imaging or medical history data.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chao Liu, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Biliary and Pancreatic Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Honghua Zhang, PhD</last_name>
    <phone>020-34078840</phone>
    <email>zhanghh68@mail.sysu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sun Yat-sen Memorial Hospital, Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510220</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Honghua Zhang, PhD</last_name>
      <phone>020-34078840</phone>
      <email>zhanghh68@mail.sysu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 16, 2022</study_first_submitted>
  <study_first_submitted_qc>November 16, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 23, 2022</study_first_posted>
  <last_update_submitted>November 16, 2022</last_update_submitted>
  <last_update_submitted_qc>November 16, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 23, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hilar Cholangiocarcinoma</keyword>
  <keyword>Lymph Node Metastasis</keyword>
  <keyword>Radiomics</keyword>
  <keyword>Machine-learning</keyword>
  <keyword>Prognosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Cholangiocarcinoma</mesh_term>
    <mesh_term>Lymphatic Metastasis</mesh_term>
    <mesh_term>Klatskin Tumor</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

